Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.therap.2020.02.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High-Dose Cyproterone Acetate and Intracranial Meningioma: Impact of the Risk Minimisation Measures Implemented in France in 2018-2019.
Pharmacoepidemiol Drug Saf
January 2025
EPI-PHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products-ANSM, French National Health Insurance-CNAM), Saint-Denis, France.
Purpose: To measure the impact of national regulatory actions implemented in France in August 2018 and June 2019 to reduce the risk of meningioma associated with the use of cyproterone acetate (CPA).
Methods: Using the French National Healthcare database, we calculated the monthly number of CPA users among cisgender women, men and transgender women in 2010-2021, the monthly proportion of users with cerebral imaging screening, and the annual rate of meningioma surgery associated with CPA use. CPA discontinuations and switches were analysed.
UPDATE ON MEDICAL TREATMENT OF ENDOMETRIOSIS: NEW DRUGS OR NEW THERAPEUTIC APPROACHES?
Gynecol Obstet Invest
December 2024
Background: No conceptually new drugs for the safe and successful cure of endometriosis are likely to become available soon. Hormonal modulation of ovarian function and suppression of menstruation remain the pillars of disease control. However, existing drugs may be used following novel modalities to limit the consequences of endometriosis progression.
View Article and Find Full Text PDFGiant Intracranial Meningiomas Requiring Surgery in 2 Transgender Women Treated With Cyproterone Acetate.
JCEM Case Rep
October 2024
Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Woolloongabba, QLD 4102, Australia.
Article Synopsis
- Progestin-associated meningioma is a rare but serious complication linked to cyproterone acetate (CPA), which is often used in feminizing hormone therapy for transgender individuals.
- Two cases of transgender women developing symptomatic giant meningiomas after using CPA are reported, illustrating that both high and low doses of CPA can lead to this condition.
- The findings emphasize the importance of monitoring for neurological side effects and recommend prescribing the lowest effective dose of CPA, while considering alternatives when possible.
Prolonged use of nomegestrol acetate and risk of intracranial meningioma: a population-based cohort study.
Lancet Reg Health Eur
July 2024
EPI-PHARE Scientific Interest Group (French National Agency for the Safety of Medicines and Health Products, and French National Health Insurance), Saint-Denis, France.
Background: Nomegestrol acetate (NOMAC) is a synthetic potent progestogen. This study aimed to assess the risk of intracranial meningioma associated with the prolonged use of NOMAC.
Methods: Observational cohort study using SNDS data (France).
Use of progestogens and the risk of intracranial meningioma: national case-control study.
BMJ
March 2024
EPI-PHARE Scientific Interest Group, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France.
Objective: To assess the risk of intracranial meningioma associated with the use of selected progestogens.
Design: National case-control study.
Setting: French National Health Data System (ie, ).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!